Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nitric oxide synthase 3 (endothelial cell) | Starlite/ChEMBL | References |
Homo sapiens | nitric oxide synthase 1 (neuronal) | Starlite/ChEMBL | References |
Homo sapiens | nitric oxide synthase 2, inducible | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0091 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0091 | 1 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0091 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0046 | 0.0151 | 0.0151 |
Brugia malayi | FAD binding domain containing protein | 0.0091 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0091 | 1 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0091 | 1 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0091 | 1 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0056 | 0.2407 | 0.2407 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0091 | 1 | 0.5 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0091 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0091 | 1 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0091 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0091 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0091 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0091 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0091 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0091 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0091 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0045 | 0 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0091 | 1 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0091 | 1 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0081 | 0.7743 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0091 | 1 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0091 | 1 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0091 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0081 | 0.7743 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0045 | 0 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0056 | 0.2407 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 1.8 uM | Inhibitory activity against human inducible nitric oxide synthase | ChEMBL. | 8576908 |
IC50 (binding) | = 1.8 uM | Inhibitory activity against human inducible nitric oxide synthase | ChEMBL. | 8576908 |
IC50 (binding) | = 3.7 uM | Inhibitory activity against human Neuronal nitric oxide synthase | ChEMBL. | 8576908 |
IC50 (binding) | = 3.7 uM | Inhibitory activity against human Neuronal nitric oxide synthase | ChEMBL. | 8576908 |
IC50 (binding) | = 8.2 uM | Inhibitory activity against human Endothelial nitric oxide synthase | ChEMBL. | 8576908 |
IC50 (binding) | = 8.2 uM | Inhibitory activity against human Endothelial nitric oxide synthase | ChEMBL. | 8576908 |
Selectivity (binding) | = 2.1 | Selectivity is defined as the ratio of the IC50(hncNOS) to IC50(hiNOS) | ChEMBL. | 8576908 |
Selectivity (binding) | = 4.6 | Selectivity is defined as the ratio of the IC50(hecNOS) to IC50(hiNOS) | ChEMBL. | 8576908 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.